← Back

Wire · operational-macro

FDA Clears Secukinumab for Use in Polymyalgia Rheumatica

Published

17 November 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at medscape.com →

◆ Verified

Fusion42 · 17 November 2026 · Fusion42 review

The FDA approved secukinumab (Cosentyx), an anti-IL-17A monoclonal antibody, for treating adults with polymyalgia rheumatica (PMR) who are steroid-refractory or intolerant. This is the first anti-IL-17 biologic and only second FDA-approved treatment for PMR, supported by the phase 3 REPLENISH trial showing doubled sustained remission rates.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

PMR treatment options just opened with secukinumab's FDA nod, putting pressure on therapies relying on steroids. You can start targeting patients who struggle with steroid side effects and shift clinical focus to biologic alternatives.

◆ Coverage

1 source · 17 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalpmrsecukinumabbiologicclinical-trial